Panja M, Maity A K, Kar A K, Chatterjee S S, Kumar S, Roy S, Sinha D P, Majumdar B, Panja S
Department of Cardiology, Institute of Post Graduate Medical Education and Research, Calcutta.
Indian Heart J. 1992 Jan-Feb;44(1):47-9.
Fifty patients with drug resistant tachyarrhythmias were treated with amiodarone for 6-22 months; 16 for recurrent ventricular tachycardia (VT), 2 for VT followed by ventricular fibrillation (VF), 14 for complex ventricular ectopics, and 18 for supraventricular tachyarrhythmias (SVT). Amiodarone was administered in a dose much lower than that used in western trials. The actual incidence of successful amiodarone therapy was 81.2% at 22 months for patients with VT. Among the patients with SVT, 88.6% patients were successfully treated for 22 months (range 3-22 months). Amiodarone toxicity appeared in 22 of 50 patients (44%) treated for more than 12 weeks. Withdrawal of therapy was required in 4 patients. Despite the lower dose, clinical efficacy and onset of action were comparable to the western experience.
50例耐药性快速心律失常患者接受了胺碘酮治疗6至22个月;其中16例为复发性室性心动过速(VT),2例为VT后发生心室颤动(VF),14例为复杂性室性早搏,18例为室上性快速心律失常(SVT)。胺碘酮的给药剂量远低于西方试验中使用的剂量。对于VT患者,胺碘酮治疗22个月时的实际成功率为81.2%。在SVT患者中,88.6%的患者在22个月(范围3至22个月)内得到成功治疗。50例接受治疗超过12周的患者中有22例(44%)出现胺碘酮毒性。4例患者需要停药。尽管剂量较低,但临床疗效和起效情况与西方经验相当。